Exclusion of Patients With Brain Metastases in Published Phase III Clinical Trials for Advanced Breast Cancer
{{output}}
Metastatic HER2-positive (HER2+) and triple-negative breast cancer (TNBC) confer a 30% or higher risk of developing brain metastases (BrM), but BrM is typically an exclusion criteria for clinical trials, which limits the generalizability of trial results to th... ...
